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BACKGROUND
Vitamin D metabolites support innate immune responses to Mycobacterium tubercu-
losis. Data from phase 3, randomized, controlled trials of vitamin D supplementa-
tion to prevent tuberculosis infection are lacking.
METHODS
We randomly assigned children who had negative results for M. tuberculosis infec-
tion according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a 
weekly oral dose of either 14,000 IU of vitamin D3 or placebo for 3 years. The 
primary outcome was a positive QFT result at the 3-year follow-up, expressed as a 
proportion of children. Secondary outcomes included the serum 25-hydroxyvita-
min D (25[OH]D) level at the end of the trial and the incidence of tuberculosis 
disease, acute respiratory infection, and adverse events.
RESULTS
A total of 8851 children underwent randomization: 4418 were assigned to the vi-
tamin D group, and 4433 to the placebo group; 95.6% of children had a baseline 
serum 25(OH)D level of less than 20 ng per milliliter. Among children with a 
valid QFT result at the end of the trial, the percentage with a positive result was 
3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the 
placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; 
P = 0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter 
in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean 
between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculo-
sis disease was diagnosed in 21 children in the vitamin D group and in 25 children 
in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 
children in the vitamin D group and 34 in the placebo group were hospitalized for 
treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 
1.40). The incidence of adverse events did not differ significantly between the two 
groups.
CONCLUSIONS
Vitamin D supplementation did not result in a lower risk of tuberculosis infection, 
tuberculosis disease, or acute respiratory infection than placebo among vitamin D– 
deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; 
ClinicalTrials.gov number, NCT02276755.)
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The End TB Strategy of the World Health Organization (WHO) calls for an 80% decrease in the incidence of tubercu-
losis by 2030.1 The mainstay of tuberculosis 
control is treatment of active tuberculosis dis-
ease to reduce transmission; however, mathe-
matical models indicate that this strategy alone 
cannot achieve the target reduction.2 This is be-
cause most cases of tuberculosis disease arise as 
a consequence of reactivation of asymptomatic 
latent Mycobacterium tuberculosis infection. It has 
been estimated that approximately 1.7 billion 
persons worldwide have latent tuberculosis in-
fection,3 and about 10% of these persons will 
have progression to tuberculosis disease in their 
lifetime.4 Although reactivation of tuberculosis 
disease usually occurs in adulthood, primary 
infection is most commonly acquired in child-
hood; therefore, measures to prevent acquisition 
of latent tuberculosis infection in children will 
need to be implemented if desired reductions in 
tuberculosis incidence are to be achieved.2
Vitamin D supplementation has been proposed 
as an intervention to reduce the risk of acquiring 
latent tuberculosis infection in populations in 
which deficiency is prevalent.5 We have previ-
ously reported that vitamin D deficiency is as-
sociated with susceptibility to latent tuberculosis 
infection in schoolchildren6; we have also found 
that vitamin D supplementation boosts immu-
nity to mycobacterial infection in persons in con-
tact with others who have tuberculosis disease7 
and reduces the risk of conversion to a positive 
result on a tuberculin skin test in schoolchil-
dren.8 A recent meta-analysis of longitudinal 
studies has shown that vitamin D deficiency 
predicts the risk of tuberculosis disease in a 
concentration-dependent manner.9
We therefore hypothesized that vitamin D 
supplementation would reduce the risk of tuber-
culosis infection and tuberculosis disease in 
populations in which both vitamin D deficiency 
and tuberculosis are prevalent. We tested this 
hypothesis in a phase 3, double-blind, random-
ized, placebo-controlled trial of vitamin D sup-
plementation in schoolchildren living in Mongo-
lia, with development of M. tuberculosis infection 
as the primary outcome and the incidence of 
active tuberculosis and acute respiratory infec-
tion as secondary outcomes.
Me thods
Trial Design, Setting, and Participants
We conducted the current trial in 18 public 
schools in Ulaanbaatar, Mongolia. Eligibility 
assessments were performed at participating 
schools by trial field workers. The main inclu-
sion criteria were an age of 6 to 13 years at 
screening and attendance at a participating 
school; principal exclusion criteria were the pres-
ence of latent tuberculosis infection (as confirmed 
by a positive result on the QuantiFERON-TB 
Gold In-Tube assay [QFT, Qiagen] at screening) 
and the presence of clinical signs of rickets.
Randomization
Eligible children were randomly assigned in a 
1:1 ratio, with stratification according to school 
of attendance, to receive one capsule per week 
containing either 14,000 IU (0.35 mg) of vitamin 
D3 or placebo for 3 years. Group assignments 
were concealed from participants, clinicians, 
and all trial staff (including senior investigators 
and persons who assessed outcomes).
Follow-up Assessments
During school terms, trial participants had week-
ly face-to-face visits at which vitamin D3 or pla-
cebo was administered and adverse events, in-
cluding incident active tuberculosis and acute 
respiratory infection, were recorded. The final 
visit at the 3-year follow-up included the same 
assessments that were performed at baseline: 
a 5-ml blood specimen was obtained for QFT 
testing and for measurement of the serum 
25-hydroxyvitamin D (25[OH]D) level. Children 
who were found to have a positive QFT result at the 
3-year follow-up were referred to the Mongolia 
National Center for Communicable Diseases for 
clinical and radiographic screening for tuberculo-
sis disease. Clinical and radiologic data for all chil-
dren for whom antituberculosis therapy was pre-
scribed were reviewed by members of the trial 
end-point committee, who classified the likelihood 
of tuberculosis disease as confirmed, probable, pos-
sible, or unlikely, according to published criteria.10
Outcomes
The primary outcome was a positive QFT result 
at the end of the trial (expressed as a proportion 
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of children), as defined by an interferon-γ level 
that was at or above the manufacturer-recom-
mended threshold value of 0.35 IU per milliliter. 
Secondary efficacy outcomes were a positive QFT 
result according to an interferon-γ level at or 
above the threshold value of 4.0 IU per milliliter 
at the end of the trial (a threshold value previ-
ously reported as indicating sustained conver-
sion11), expressed as a proportion of children; 
the mean antigen-stimulated interferon-γ level; 
tuberculosis disease, as diagnosed by clinicians 
in Mongolia and adjudicated by the trial end-
point committee; at least one hospitalization for 
treatment of acute respiratory infection; at least 
one episode of symptoms of acute respiratory 
infection; receipt of at least one course of anti-
biotic agents for treatment of acute respiratory 
infection; the mean serum 25(OH)D level at the 
end of the trial; and a serum 25(OH)D level of 
more than 20 ng per milliliter (50 nmol per liter) 
at the end of the trial. Safety outcomes were 
death, serious adverse events, adverse events re-
sulting in discontinuation of the trial regimen, 
and other monitored safety conditions, including 
hypercalcemia (serum corrected calcium level, 
>2.55 mmol per liter [10.2 mg per deciliter], 
confirmed on two samples), hypervitaminosis D 
(25[OH]D level, >80 ng per milliliter [200 nmol 
per liter]), and renal stones.
Statistical Analysis
Assuming a 2% annual risk of tuberculosis in-
fection, an 18% loss to follow-up, and 5% inde-
terminate QFT tests at the end of the trial, we 
calculated that enrollment of 8850 participants 
would give the trial 80% power at a type I error 
rate of 5% to detect a 25% reduction with sup-
plementation in the percentage of children with 
a positive QFT result at the 3-year follow-up. 
Statistical analyses were performed according to 
the intention-to-treat principle, with a 5% signifi-
cance level. Treatment effects for dichotomous 
outcomes were estimated with the use of the 
Mantel–Haenszel risk ratio, with stratification 
according to school, and are reported as risk 
ratios with 95% confidence intervals, adjusted for 
school of attendance. Additional details regard-
ing statistical methods are provided in the Sup-
plementary Appendix and the protocol, both avail-
able with the full text of this article at NEJM.org.
R esult s
Participants
From September 2015 through March 2017, a 
total of 11,475 children were invited to partici-
pate in the trial. Of these children, 9814 under-
went QFT testing. Among the 8851 children who 
had a negative QFT result, 4418 were randomly 
assigned to receive vitamin D3 and 4433 to re-
ceive placebo (Fig. 1). The mean age of the chil-
dren was 9.4 years, 49.3% were female, and 
80.1% had a bacille Calmette–Guérin vaccina-
tion scar. The mean serum 25(OH)D level was 
11.9 ng per milliliter (30 nmol per liter); 95.6% 
of children had a 25(OH)D level below 20 ng per 
milliliter, and 31.8% had a 25(OH)D level below 
10 ng per milliliter (25 nmol per liter). The char-
acteristics of the children were balanced be-
tween the two groups (Table 1).
The median follow-up was 3.0 years (inter-
quartile range, 2.9 to 3.1) in both groups, and the 
median number of doses of vitamin D or place-
bo that were administered was 152 (interquartile 
range, 138 to 158). Valid QFT results at the end 
of the trial were obtained for 8117 participants 
(91.7% of the children who underwent random-
ization) who were included in the analysis of the 
primary outcome; a total of 8819 children had at 
least one follow-up visit and had data included 
in the analyses of the incidence of active tuber-
culosis and the incidence of acute respiratory 
infection. Follow-up 25(OH)D levels were avail-
able for all children who had available QFT re-
sults at the end of the trial; the mean 25(OH)D 
level at 3 years was higher in the vitamin D group 
than in the placebo group (31.0 vs. 10.7 ng per 
milliliter [75 nmol per liter vs. 25 nmol per liter]; 
difference, 20.3 ng per milliliter [50 nmol per li-
ter]; 95% confidence interval [CI] for difference, 
19.9 to 20.6) (Fig. 2). At the end of the trial, 
89.8% of children in the vitamin D group and 5.6% 
in the placebo group had a 25(OH)D level of 20 ng 
or higher per milliliter.
Primary and Secondary Outcomes
At the 3-year follow-up, conversion to a positive 
QFT result, as defined by an interferon-γ level 
that was at or above the threshold value of 0.35 IU 
per milliliter (the primary outcome), occurred in 
281 children. The percentage of children with a 
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positive QFT result was similar in the two 
groups: 3.6% (147 of 4074 children) in the vita-
min D group and 3.3% (134 of 4043) in the 
placebo group (adjusted risk ratio, 1.10; 95% CI, 
0.87 to 1.38; P = 0.42) (Table 2). In the overall 
trial population, no significant between-group 
difference was observed in the proportion of 
children who had QFT conversion according to 
an interferon-γ level that was at or above the 
threshold value of 4.0 IU per milliliter (adjusted 
risk ratio, 0.67; 95% CI, 0.39 to 1.12). We found 
no evidence to suggest that assignment to the 
vitamin D group rather than to the placebo 
group had an effect on the mean antigen-stimu-
lated interferon-γ level in QFT supernatants, 
either in the overall population (adjusted mean 
difference between groups, −0.01 IU; 95% CI, 
−0.04 to 0.02) or in the subgroup of children 
with a baseline 25(OH)D level below 10 ng per 
milliliter (adjusted mean difference between 
groups, −0.04 IU; 95% CI, −0.09 to 0.02) (Table 
S1 in the Supplementary Appendix).
Figure 1. Screening, Randomization, and Follow-up.
QFT denotes QuantiFERON-TB Gold In-Tube assay.
8851 Children with negative QFT results
underwent randomization
11,475 Children were invited to participate
1065 Declined to participate or
parent did not give consent
596 Were ineligible
9814 Underwent QFT testing
946 Had positive QFT result
4 Had indeterminate QFT result
13 Had negative QFT result but
declined to participate further
4418  Were assigned to receive vitamin D3 4433 Were assigned to receive placebo
14 Withdrew before receipt of
first dose
17 Withdrew before receipt of
first dose
4401 Received at least one dose of
 vitamin D3




134 Were lost to follow-up
61 Completed follow-up,
but did not have QFT
test result available
1 Had QFT test result that
could not be determined
6 Died
161 Withdrew
146 Were lost to follow-up
63 Completed follow-up,
but did not have QFT
test result available
4074 Were included in the primary 
outcome analysis of QFT results
4043 Were included in the primary 
outcome analysis of QFT results
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Post Hoc Analysis
Subgroup analysis revealed no evidence to sug-
gest heterogeneity of treatment effect for the 
outcome of QFT conversion according to an 
interferon-γ level at or above the threshold value 
of 0.35 IU per milliliter in children with a base-
line 25(OH)D level of less than 10 ng per milli-
liter as compared with children with a level of 
10 ng or higher per milliliter. However, subgroup 
analysis of QFT conversion at the threshold value 
of 4.0 IU per milliliter raised the possibility that 
in children with a baseline 25(OH)D level below 








Age — yr 9.4±1.6 9.4±1.6 9.4±1.6
Female sex — no. (%) 4366 (49.3) 2142 (48.5) 2224 (50.2)
Ethnic group — no. (%)†
Khalkh 8165 (92.2) 4062 (91.9) 4103 (92.6)
Other 686 (7.8) 356 (8.1) 330 (7.4)
Highest educational level attained by either  
parent — no. (%)
Secondary school or lower 4858 (54.9) 2401 (54.3) 2457 (55.4)
University or polytechnic institution 3993 (45.1) 2017 (45.7) 1976 (44.6)
Type of residence — no. (%)
Yurt 3271 (37.0) 1643 (37.2) 1628 (36.7)
House without central heating 3387 (38.3) 1665 (37.7) 1722 (38.8)
House with central heating 2193 (24.8) 1110 (25.1) 1083 (24.4)
Home owned by family — no. (%) 6963 (78.7) 3493 (79.1) 3470 (78.3)
Monthly household income — U.S. dollars‡ 848±579 851±554 846±604
Tobacco smoking in the household — no. (%)§ 3143 (35.5) 1570 (35.5) 1573 (35.5)
Child actively smoking — no. (%)  47 (0.5)  26 (0.6)  21 (0.5)
History of pulmonary tuberculosis in a household 
member — no. (%)
215 (2.4) 108 (2.4) 107 (2.4)
Bacille Calmette–Guérin scar — no. (%) 7091 (80.1) 3527 (79.8) 3564 (80.4)
Body-mass index z score¶  0.2±1.1  0.2±1.0  0.2±1.1
Height z score for age‖ −0.3±1.0 −0.3±1.0 −0.3±1.0
Serum 25(OH)D level — ng/ml
Mean value** 11.9±4.2 11.9±4.2 11.9±4.2
Distribution — no./total no. (%)
<10.0 2813/8846 (31.8) 1393/4417 (31.5) 1420/4429 (32.1)
10.0–19.9 5640/8846 (63.8) 2828/4417 (64.0) 2812/4429 (63.5)
20.0–29.9 381/8846 (4.3) 188/4417 (4.3) 193/4429 (4.4)
≥30.0 12/8846 (0.1) 8/4417 (0.2) 4/4429 (0.1)
*  Plus–minus values are means ±SD. To convert the 25-hydroxyvitamin D (25[OH]D) values to nanomoles per liter, 
multiply by 2.496. Percentages may not total 100 because of rounding.
†  Ethnic group was reported by the caregivers.
‡  Data were missing for 1 household in each group.
§  Tobacco smoking in the household was defined as 1 or more persons in the household smoking indoors.
¶  Data for body-mass index (the weight in kilograms divided by the square of the height in meters) z score were miss-
ing for 1 child in the placebo group.
‖  Data were missing for 1 child in the placebo group.
**  The 25(OH)D values have been adjusted for seasonal variation. Data were missing for 1 child in the vitamin D group 
and 4 children in the placebo group.
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10 ng per milliliter, the risk of QFT conversion 
at this higher cutoff was lower among children 
assigned to receive vitamin D than among those 
assigned to placebo (adjusted risk ratio, 0.41; 
95% CI, 0.17 to 0.99); this result was not seen in 
children with a baseline 25(OH)D level of 10 ng 
or higher per milliliter (adjusted risk ratio, 0.90; 
95% CI, 0.46 to 1.77) (Table 2). The results of 
this subgroup analysis should be interpreted 
with caution, given that there was no adjustment 
for multiple comparisons and the analysis was 
performed post hoc.
Tuberculosis Disease
Tuberculosis disease was diagnosed by local 
doctors in 46 children during the trial. These 
events were evenly distributed between the two 
groups: among children who had at least one 
follow-up visit at which they were assessed for 
tuberculosis disease, 21 of 4401 (0.5%) children 
in the vitamin D group and 25 of 4418 (0.6%) 
children in the placebo group received a diagno-
sis of tuberculosis (adjusted risk ratio, 0.87; 95% 
CI, 0.49 to 1.55). A total of 26 of these children 
were classified as having confirmed or probable 
tuberculosis disease by the trial end-point com-
mittee and were also evenly distributed between 
groups (13 of 4401 children in the vitamin D 
group and 13 of 4418 children in the placebo 
group; adjusted risk ratio, 1.05; 95% CI, 0.49 to 
2.27). Subgroup analysis revealed no heterogene-
ity of treatment effect for either outcome in 
children with a baseline 25(OH)D level of less 
than 10 ng per milliliter or in children with a 
level of 10 ng or higher per milliliter (Table 2).
Acute Respiratory Infection
Among children who had at least one follow-up 
visit at which they were assessed for acute respi-
ratory infection, 63 children had at least one 
hospitalization for treatment of acute respiratory 
infection (29 of 4401 children in the vitamin D 
group and 34 of 4418 in the placebo group; ad-
justed risk ratio, 0.86; 95% CI, 0.52 to 1.40). No 
between-group difference was seen in the pro-
portion of children who had at least one episode 
of symptoms of acute respiratory infection (ad-
justed risk ratio, 1.00; 95% CI, 0.98 to 1.02) or 
who were receiving at least one course of antibi-
otics for treatment of acute respiratory infection 
(adjusted risk ratio, 0.99; 95% CI, 0.93 to 1.05). 
No effect of the intervention was seen when the 
proportions of children who reported upper or 
lower acute respiratory infection were analyzed 
separately (Table S2). Subgroup analyses revealed 
no heterogeneity of treatment effect for acute 
respiratory infection outcomes in children with 
a baseline 25(OH)D level below 10 ng per milli-
liter or in those with a level of 10 ng or higher 
per milliliter (Table 2).
Sensitivity Analyses
With respect to all the outcomes described above, 
the results were materially unchanged when in-
verse probability weighting was used to correct 
for any potential bias due to missing data. Ad-
ditional information is provided in Table S3.
Adverse Events
A total of 10 children (4 in the vitamin D group 
and 6 in the placebo group) died during the 
trial, and 324 (142 in the vitamin D group and 
182 in the placebo group) had one or more non-
fatal serious adverse events (Table 3 and Table 
S4). None of these events were judged to be re-
lated to vitamin D or placebo. Symptomatic hyper-
calcemia developed in 1 child in the vitamin D 
group who had a corrected serum calcium level 
of 2.70 mmol per liter (10.8 mg per deciliter). 
Figure 2. Mean Serum 25-Hydroxyvitamin D (25[OH]D) Level According to 
Time and Trial Group.
Levels of 25(OH)D were higher at the end of the trial in the group that re-
ceived vitamin D supplementation than in the placebo group (mean between-
group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). To convert 
the 25(OH)D values to nanomoles per liter, multiply by 2.496. I bars indi-
cate the standard deviation. The plus–minus values are means ±SD. The 
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Table 2. Respiratory Infection.
Variable Vitamin D Placebo
Adjusted Risk Ratio 
(95% CI)*
Tuberculosis infection according to positive QFT result†
Interferon-γ level ≥0.35 IU/ml — no./total no. (%)‡
Overall 147/4074 (3.6) 134/4043 (3.3) 1.10 (0.87–1.38)§
Baseline 25(OH)D level <10 ng/ml 64/1288 (5.0) 64/1304 (4.9) 1.01 (0.72–1.42)
Baseline 25(OH)D level ≥10 ng/ml 83/2785 (3.0) 70/2736 (2.6) 1.17 (0.86–1.61)
Interferon-γ level ≥4.0 IU/ml — no./total no. (%)
Overall 23/4074 (0.6) 35/4043 (0.9) 0.67 (0.39–1.12)
Baseline 25(OH)D level <10 ng/ml 7/1288 (0.5) 17/1304 (1.3) 0.41 (0.17–0.99)
Baseline 25(OH)D level ≥10 ng/ml 16/2785 (0.6) 18/2736 (0.7) 0.90 (0.46–1.77)
Tuberculosis disease status¶
Starting treatment for tuberculosis disease — no./ 
total no. (%)
Overall 21/4401 (0.5) 25/4418 (0.6) 0.87 (0.49–1.55)
Baseline 25(OH)D level <10 ng/ml 10/1387 (0.7) 15/1414 (1.1) 0.67 (0.30–1.47)
Baseline 25(OH)D level ≥10 ng/ml 11/3013 (0.4) 10/3000 (0.3) 1.17 (0.50–2.75)
Confirmed or probable tuberculosis disease, as adjudicated 
by the trial end-point committee — no./total no. (%)
Overall 13/4401 (0.3) 13/4418 (0.3) 1.05 (0.49–2.27)
Baseline 25(OH)D level <10 ng/ml 6/1387 (0.4) 8/1414 (0.6) 0.75 (0.26–2.14)
Baseline 25(OH)D level ≥10 ng/ml 7/3013 (0.2) 5/3000 (0.2) 1.47 (0.47–4.61)
Acute respiratory infection¶
Participant hospitalized for ≥1 episode — no./total no. (%)
Overall 29/4401 (0.7) 34/4418 (0.8) 0.86 (0.52–1.40)
Baseline 25(OH)D level <10 ng/ml 8/1387 (0.6)‖ 10/1414 (0.7)** 0.81 (0.32–2.09)
Baseline 25(OH)D level ≥10 ng/ml 21/3013 (0.7)†† 24/3000 (0.8)‡‡ 0.86 (0.48–1.55)
Participant reported ≥1 episode — no./total no. (%)
Overall 3783/4401 (86.0) 3793/4418 (85.9) 1.00 (0.98–1.02)
Baseline 25(OH)D level <10 ng/ml 1195/1387 (86.2) 1205/1414 (85.2) 1.01 (0.98–1.04)
Baseline 25(OH)D level ≥10 ng/ml 2587/3013 (85.9) 2585/3000 (86.2) 1.00 (0.98–1.02)
Participant received ≥1 course of antibiotics for episode  
— no./total no. (%)
Overall 1272/4401 (28.9) 1292/4418 (29.3) 0.99 (0.93–1.05)
Baseline 25(OH)D level <10 ng/ml 392/1387 (28.3) 399/1414 (28.2) 0.99 (0.88–1.12)
Baseline 25(OH)D level ≥10 ng/ml 880/3013 (29.2) 892/3000 (29.7) 0.98 (0.91–1.06)
*  The risk ratios were adjusted for school of attendance.
†  Data for the baseline 25(OH)D level were unavailable for 4 children included in the overall analysis of QFT results (1 of 4074 children in 
the vitamin D group and 3 of 4043 children in the placebo group).
‡  The primary outcome was a positive QFT result, as defined by an interferon-γ level that was at or above the threshold value of 0.35 IU per 
milliliter, expressed as a proportion of children.
§  P = 0.42.
¶  Data for the baseline 25(OH)D level were unavailable for 5 children included in the overall analysis of tuberculosis disease and acute re-
spiratory infection (1 of 4401 children in the vitamin D group and 4 of 4418 children in the placebo group).
‖  A total of 5 children had lower respiratory infections, and 3 had upper respiratory infections.
**  A total of 9 children had lower respiratory infections, and 1 had an upper respiratory infection.
††  A total of 18 children had lower respiratory infections, and 3 had upper respiratory infections.
‡‡  A total of 21 children had lower respiratory infections, and 3 had upper respiratory infections.
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The hypercalcemia manifested with nausea and 
epigastric discomfort; vitamin D was discontin-
ued, and the hypercalcemia and symptoms re-
solved. Three children had a serum 25(OH)D 
level that was higher than 80 ng per milliliter at 
the 3-year follow-up (87.6 ng per milliliter [219 
nmol per liter], 93.6 ng per milliliter [234 nmol 
per liter], and 95.7 ng per milliliter [239 nmol 
per liter]); none of the children had symptoms. 
A total of 15 nonfatal adverse events led to dis-
continuation of the trial regimen (in 10 children 
in the vitamin D group and 5 in the placebo 
group).
Discussion
We report the results of a phase 3, randomized, 
controlled trial that investigated whether vita-
min D supplementation reduces the risk of inci-
dent tuberculosis infection and disease; this 
large trial also assessed the effects of this inter-
vention on the risk of acute respiratory infection. 
Vitamin D deficiency was highly prevalent in the 
trial population at baseline; at the end of the trial, 
25(OH)D levels were elevated to the physiologic 
range among children assigned to the vitamin D 
group. However, we observed no between-group 
difference in the proportion of children with 
QFT conversion according to an interferon-γ level 
at or above the threshold value of 0.35 IU per 
milliliter (the primary outcome), either in the 
trial population as a whole or among children in 
the vitamin D group who had a baseline 25(OH)
D level below 10 ng per milliliter (31.8%). The 
intervention also had no effect on the incidence 
of tuberculosis disease or acute respiratory in-
fection. Oral vitamin D supplementation at a 
weekly dose of 14,000 IU was safe and did not 
cause unacceptable side effects. The incidence of 
adverse events was balanced between the two 
groups, and no serious adverse event was attrib-
uted to vitamin D or placebo.
The null finding for the primary outcome 
contrasts with positive findings from a cross-
sectional analysis and a pilot intervention study 
that was performed in the same population.6,8 
The results of cross-sectional studies are poten-
tially vulnerable to the effects of unmeasured or 
residual confounding or reverse causality. The 
positive result of our pilot study may have been 
due to the type I error (the P value for the pri-
mary outcome of a conversion to a positive tu-
berculin skin test was 0.06) or the different 
methods used to assess M. tuberculosis infection 
Table 3. Adverse Events.*
Variable Vitamin D (N = 4401) Placebo (N = 4419)
Incidence Rate 


















Death 4 0.03 4 6 0.05 6 0.67 (0.19–2.37)
Serious adverse event 159 1.25 146 191 1.50 188 0.83 (0.68–1.03)
Nonfatal adverse event leading 
to discontinuation of trial 
regimen
10 0.08 10 5 0.04 5 2.00 (0.68–5.86)
Other monitored safety  
conditions
Hypercalcemia† 1 0.01 1 0 0 0 NC
Hypervitaminosis D‡ 3 0.02 3 0 0 0 NC
Renal stones 0 0 0 0 0 0 NC
*  Included are children who received at least one dose of vitamin D or placebo. Details about deaths and serious adverse events are provided 
in Table S4 in the Supplementary Appendix. NC indicates that the incidence rate ratio could not be calculated because of an absence of 
events in one or both groups.
†  Hypercalcemia was defined as a corrected serum calcium level higher than 2.55 mmol per liter (10.2 mg per deciliter), as confirmed on re-
peat testing.
‡  Hypervitaminosis D was defined as a serum 25(OH)D level higher than 80 ng per milliliter.
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(tuberculin skin test in the previous study and 
QFT in the current trial).
The current trial also showed no effect of vi-
tamin D supplementation on the incidence of 
acute respiratory infection. This finding contrasts 
with results of our previous clinical trial involv-
ing Mongolian schoolchildren, in which the rate 
of participant-reported acute respiratory infec-
tion among children who were assigned to daily 
ingestion of milk fortified with 300 IU of vita-
min D3 during the winter was 50% lower than 
that among children in the control group.12 The 
contrasting results of these two trials may re-
flect differences in the amount, frequency, and 
duration of vitamin D3 administration or the 
coadministration with milk in the previous trial.
Our trial has several strengths. In contrast to 
recent large clinical trials of vitamin D supple-
mentation,13-15 the prevalence of vitamin D defi-
ciency at baseline was very high among partici-
pants (95.6% of children had a 25[OH]D level of 
<20 ng per milliliter). We used a weekly regimen 
of vitamin D supplementation, which allowed 
for direct observation of administration to en-
courage adherence and avoided the large fluc-
tuations in 25(OH)D levels that are seen when 
vitamin D is administered in longer and more 
widely spaced bolus doses.13,16 Therefore, our null 
results for the primary outcome of this trial can-
not be readily attributed to a lack of participants 
with low vitamin D levels at baseline or to ad-
ministration of a regimen that was potentially 
ineffective from a pharmacokinetic perspective. 
Other strengths include high retention (91.7%); 
use of QFT testing to assess tuberculosis infec-
tion (as opposed to tuberculin skin testing, 
which may yield false positive results because of 
previous bacille Calmette–Guérin vaccination or 
exposure to environmental mycobacteria); use 
of an externally accredited laboratory and the very 
low number of indeterminate results (the result 
of 1 of the 8118 follow-up QFT tests that were 
performed could not be determined); and stan-
dardization of serum 25(OH)D measurements17 
with the use of standards provided by the Vita-
min D External Quality Assessment Scheme.
Our trial also has some limitations. The 3.5% 
incidence of QFT conversion as defined by an 
interferon-γ level at or above the threshold value 
of 0.35 IU per milliliter was lower than the antici-
pated incidence of 5.9%, which rendered our trial 
as potentially underpowered. However, the 95% 
confidence interval for the adjusted risk ratio 
(0.87 to 1.38) effectively rules out a relative risk 
reduction of more than 13%. An effect of this 
size or less is unlikely to be considered of suf-
ficient magnitude to warrant the population-
level intervention that would be needed to ele-
vate 25(OH)D levels into the physiologic range. 
An additional consideration is our use of the 
manufacturer-recommended cutoff of an inter-
feron-γ level of 0.35 IU per milliliter to indicate 
QFT conversion. In the time since we designed 
the trial, other researchers have reported that 
reversion to a negative result is common at this 
threshold.18 By contrast, conversion at the higher 
threshold of 4.0 IU per milliliter has recently 
been reported to be more sustained than at the 
threshold of 0.35 IU per milliliter.11 We therefore 
prespecified QFT conversion at the threshold of 
4.0 IU per milliliter as a secondary outcome in 
our analysis plan. No significant effect of the 
intervention on this outcome was seen in the 
trial population as a whole, but a post hoc sub-
group analysis raised the possibility of an effect 
in children with baseline 25(OH)D levels below 
10 ng per milliliter; however, the results of this 
subgroup analysis should be interpreted with 
caution, given that the analysis was performed 
post hoc and there was no adjustment for mul-
tiple comparisons. Additional follow-up is there-
fore planned to determine whether the interven-
tion had an effect on sustained QFT conversion 
in the trial population.
In conclusion, we found that weekly oral 
supplementation with 14,000 IU of vitamin D3 
for 3 years was effective in safely elevating 
25(OH)D levels in a very large population of vi-
tamin D–deficient schoolchildren in Mongolia. 
However, this intervention did not result in a 
lower risk of primary tuberculosis infection, as 
indicated by QFT conversion at the threshold 
value for the interferon-γ level of 0.35 IU per 
milliliter, than placebo.
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